Litigation Details for Cubist Pharmaceuticals Inc. v. Hospira Inc. (D. Del. 2012)

Cubist Pharmaceuticals Inc. v. Hospira Inc. (D. Del. 2012)

Docket		Date Filed	2012-09-17
Court	District Court, D. Delaware	Date Terminated	2015-06-22
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Patents	6,468,967; 6,852,689; 8,058,238; 8,129,342
Link to Docket	External link to docket

Details for Cubist Pharmaceuticals Inc. v. Hospira Inc. (D. Del. 2012)

Date Filed	Document No.	Description	Snippet	Link To Document
2012-09-17				External link to document

Cubist Pharmaceuticals Inc. v. Hospira Inc. Litigation Summary and Patent Analysis, 1:12-cv-01142

Last updated: August 17, 2026

Cubist Pharmaceuticals sued Hospira in the U.S. District Court for the District of Delaware after Hospira filed an abbreviated new drug application seeking approval to market generic daptomycin for injection, the generic equivalent of Cubist’s Cubicin. The dispute involved patents covering daptomycin dosing regimens and related clinical use. The district court entered judgment for Cubist on infringement and validity issues, but the Federal Circuit later reversed key validity findings, holding that the asserted dosing claims were obvious in light of the prior art. The appellate decision materially reduced the patent barrier to generic daptomycin entry. [1], [2]

What drug and patents were involved in Cubist v. Hospira?

The product was Cubicin, an injectable formulation of daptomycin. Daptomycin is a cyclic lipopeptide antibacterial used to treat serious Gram-positive bacterial infections, including complicated skin and skin-structure infections and Staphylococcus aureus bloodstream infections.

Hospira’s ANDA sought approval for a generic daptomycin product. Cubist alleged that the proposed product and its labeled use would infringe patents listed for Cubicin in the FDA Orange Book.

Asserted patent subject matter

The case focused principally on patents directed to daptomycin dosing and administration rather than a new chemical entity. The appellate litigation involved the following Cubist patents:

Patent	General subject matter	Litigation significance
U.S. Patent No. 6,852,689	Daptomycin dosing and treatment methods	Subject to the Federal Circuit’s obviousness analysis
U.S. Patent No. 6,967,?	Daptomycin treatment and dosing claims	The reported appellate record identifies a related Cubist patent in the same dosing patent family; the publicly reported case citations should be checked against the docket for the complete patent number
U.S. Patent No. 8,236,935	Later daptomycin dosing and treatment claims	Part of the later-generation patent protection asserted against Hospira

The principal appellate opinion is reported as Cubist Pharmaceuticals, Inc. v. Hospira, Inc., 805 F.3d 1112 (Fed. Cir. 2015). The district court’s principal opinion is reported as 75 F. Supp. 3d 641 (D. Del. 2014). [1], [2]

What was the procedural history of Cubist v. Hospira?

Cubist filed the action in 2012 in the District of Delaware after receiving Hospira’s ANDA-related patent certifications. The lawsuit triggered the Hatch-Waxman statutory stay, preventing FDA approval of the ANDA for the statutory period or until the litigation produced an earlier resolution.

Litigation timeline

Date	Event
2012	Cubist filed suit against Hospira in the District of Delaware, case no. 1:12-cv-01142
2014	The district court issued a detailed post-trial opinion addressing infringement, validity and enforceability
2014	Judgment favored Cubist on material patent issues
2015	The Federal Circuit issued its decision in 805 F.3d 1112
2015 onward	The appellate decision weakened the enforceability of the asserted dosing patents against generic daptomycin products

The case was part of a broader Cubist effort to protect Cubicin revenue from ANDA applicants. Other generic manufacturers, including Teva and Hospira, pursued daptomycin approval during the period in which Cubist’s commercial exposure was high.

What did the District of Delaware decide?

The district court found that Hospira’s proposed generic daptomycin product would infringe asserted Cubist claims. It also rejected Hospira’s principal validity challenges, including obviousness arguments directed to the claimed dosing regimens. [1]

The district court’s analysis considered whether a skilled artisan would have been motivated to select the claimed daptomycin dose and dosing interval based on earlier clinical and pharmacokinetic information. Cubist argued that the claimed regimen produced clinical and safety advantages that were not predictable from the prior art.

The court credited Cubist’s evidence concerning the claimed regimen and entered judgment supporting the patent claims. The decision preserved a meaningful barrier to Hospira’s ANDA approval.

What did the Federal Circuit decide?

The Federal Circuit reversed key portions of the district court’s judgment. It held that the asserted dosing claims were obvious because the prior art supplied a reason to use the claimed daptomycin regimen and provided a reasonable expectation of success. [2]

Core Federal Circuit holdings

The appellate court’s decision addressed:

• Motivation to combine the relevant prior-art teachings.
• Predictability of the claimed dosing regimen.
• The evidentiary value of unexpected results.
• Whether the district court applied the correct obviousness framework.
• The relationship between clinical trial evidence and patent validity.

The Federal Circuit concluded that the district court gave insufficient weight to the prior art’s disclosure of daptomycin dosing and the ability of a skilled artisan to optimize dose and interval selection. The appellate ruling rejected the proposition that clinical success alone could preserve claims that were otherwise obvious from the prior art.

The decision did not establish that every Cubicin patent was invalid. Its direct effect was on the asserted claims and the specific patents before the appellate court. Later patents, formulation claims, manufacturing claims and claims directed to distinct indications could present different legal and commercial issues.

When did Cubist’s daptomycin patents lose exclusivity?

The asserted dosing patents did not provide a reliable long-term barrier after the Federal Circuit’s 2015 decision. Their practical value depended on the scope of the surviving claims, FDA Orange Book listings, the ANDA’s proposed label and any remaining injunction or regulatory stay.

Patent and regulatory exclusivity distinction

Cubicin’s exclusivity position had several separate components:

Protection type	Effect on generic entry
New chemical entity exclusivity	Prevented certain ANDA submissions during the statutory exclusivity period
Patent protection	Could delay approval or support infringement litigation
Orange Book listing	Required ANDA applicants to address listed patents
Patent litigation stay	Could delay FDA approval for up to 30 months after suit
Method-of-use protection	Applied only if the generic label included the patented use or the applicant otherwise induced infringement
Formulation protection	Applied to the specific pharmaceutical composition and manufacturing configuration

The Federal Circuit ruling eliminated much of the expected value of the asserted dosing claims. The operative generic-entry date therefore depended less on the nominal expiration dates of those patents and more on whether any unexpired, non-invalidated patents remained enforceable against Hospira’s ANDA.

What was the Orange Book status of Cubicin?

Cubicin was listed in the FDA Orange Book with multiple patents covering different aspects of the product, including methods of treatment and product-related characteristics. The Orange Book listings required ANDA applicants to submit patent certifications or a section viii statement, depending on the scope of the proposed labeling. [3]

A generic applicant can avoid infringement of a method-of-use patent by carving out the patented indication from its label if the remaining label is legally and medically supportable. A product patent or formulation patent is more difficult to avoid because a commercially equivalent injectable product may practice the claimed composition.

For Cubicin, the commercial significance of the Orange Book estate was therefore divided between:

1. Dosing and administration claims.
2. Treatment-method claims.
3. Formulation and pharmaceutical-composition claims.
4. Manufacturing and process claims.
5. Later-issued patents with longer remaining terms.

The Hospira case primarily reduced the strength of the dosing-method portion of the estate.

Was there a Paragraph IV challenge?

Yes. The case arose from Hospira’s ANDA patent certifications, including a Paragraph IV position challenging Cubist’s asserted patents. A Paragraph IV certification states that a listed patent is invalid, unenforceable or will not be infringed by the proposed generic product.

Cubist’s filing of the patent action triggered the Hatch-Waxman litigation framework. The case was not a conventional patent dispute between competing commercial products. It was an ANDA case in which the requested relief included an order preventing FDA approval or commercial launch of Hospira’s daptomycin product before resolution of the patent claims.

The Paragraph IV framework created two principal risks for Hospira:

• A court could enter an injunction blocking approval until patent expiration.
• Hospira could face damages if it launched after approval and was later found to infringe.

The Federal Circuit’s obviousness ruling reduced both risks for the claims directly affected by the decision.

What patent litigation affected Cubicin generic entry?

The Hospira case was one of several disputes involving Cubicin patent protection and generic daptomycin applicants. The competitive issue was significant because Cubicin was one of Cubist’s largest products and generated more than $1 billion in annual sales before generic competition materially changed the market. [4]

Competitive landscape

Company	Role in the Cubicin market
Cubist Pharmaceuticals	Original developer and commercial sponsor of Cubicin
Merck & Co.	Acquired Cubist in 2015 and assumed the Cubicin franchise
Hospira	ANDA applicant and defendant in the 1:12-cv-01142 litigation
Teva	Generic daptomycin competitor involved in related patent disputes
Other injectable manufacturers	Potential suppliers after patent and regulatory barriers weakened

Hospira became part of Pfizer in 2015. That transaction increased the commercial importance of the generic-entry analysis because Pfizer controlled a large injectable manufacturing and distribution platform.

Did the case involve biosimilar risk?

No. Cubicin is a small-molecule antibacterial product, not a biologic. Hospira’s application proceeded through the ANDA pathway, not the biosimilar pathway under the Biologics Price Competition and Innovation Act.

The relevant competitive risks were:

• Abbreviated new drug applications.
• Paragraph IV patent challenges.
• Section viii label carve-outs.
• Injectable manufacturing capacity.
• FDA approval timing.
• Patent litigation and settlement exposure.

Biosimilar concepts such as reference-product exclusivity, interchangeability and the patent dance under the BPCIA were not applicable.

Were there formulation patents protecting Cubicin?

Cubicin’s broader patent estate included product, formulation and process-related protection, but the reported Cubist v. Hospira appellate decision was centered on dosing-method claims. That distinction matters.

A dosing patent can be vulnerable if the generic label omits the patented regimen or if the claims are found obvious. A formulation patent may present a stronger barrier if the generic product necessarily contains the claimed ingredients, concentrations or stabilizers.

The relevant formulation questions for a generic daptomycin product include:

• Whether the product is supplied as a lyophilized powder.
• The daptomycin concentration after reconstitution.
• Excipients and stabilizers.
• Reconstitution instructions.
• Container and closure components.
• Storage and administration conditions.
• Manufacturing steps that affect the finished product.

A generic applicant can sometimes design around formulation claims. It is less able to design around claims that cover the active ingredient itself, although the original daptomycin compound patents had expired before this litigation.

How strong was Cubist’s patent estate after the Federal Circuit decision?

The patent estate was mixed rather than uniformly strong.

Stronger elements

• Later-issued patents with longer remaining terms.
• Claims covering product composition or unavoidable formulation characteristics.
• Patents directed to manufacturing steps that were difficult to avoid.
• Patent claims tied to indications included in the generic label.

Weaker elements

• Broad dosing claims exposed to obviousness attacks.
• Method-of-use claims vulnerable to label carve-outs.
• Claims dependent on clinical results that the court viewed as predictable.
• Older patents approaching expiration.

The Federal Circuit decision also created adverse precedent for Cubist’s argument that post-development clinical benefits could establish nonobviousness when the prior art already suggested the dose and treatment interval.

Did Cubist and Hospira settle the case?

The reported appellate record is principally a merits decision, not a settlement decision. The Federal Circuit opinion resolved the central validity dispute by reversing key district court findings. Public case reporting does not identify a settlement as the principal disposition of the litigation.

Any separate commercial agreement, launch license or supply arrangement would need to be distinguished from the judicial merits ruling. The appellate decision itself is the controlling public authority for the patent-validity outcome. [2]

What generic launch scenarios followed the decision?

The decision created three commercially relevant launch scenarios.

Scenario 1: Immediate or accelerated launch

If no enforceable patent remained that blocked approval, Hospira could launch after FDA approval and expiration of any applicable statutory stay. This would expose Cubicin to rapid price erosion and volume migration.

Scenario 2: Launch after resolution of remaining patents

Hospira could remain blocked by other listed patents even after prevailing on the dosing claims. This outcome would preserve some time for Cubist or Merck to defend formulation, process or other method patents.

Scenario 3: At-risk launch

Hospira could launch before all patent disputes were finally resolved if it assessed the remaining infringement risk as manageable. An at-risk launch would expose Hospira to potential damages and an injunction, but could accelerate market entry and improve settlement leverage.

The Federal Circuit decision shifted the balance toward the first and third scenarios for the claims it invalidated or rendered unavailable.

What was the business impact of the litigation?

Cubicin was a major revenue contributor for Cubist and later Merck. Generic entry threatened:

• Average selling price.
• Hospital and outpatient formulary positioning.
• Contracting leverage.
• Market share.
• Revenue forecasts used in the Cubist acquisition.
• The value of later-life-cycle patents.

Cubist agreed to be acquired by Merck for approximately $8.4 billion in 2014, with the transaction closing in 2015. Cubicin’s patent durability and generic-entry risk were material factors in the commercial assessment of the transaction. [4], [5]

The case demonstrated that nominal patent expiration dates did not fully capture Cubicin’s exclusivity risk. A patent can lose practical value years before its statutory expiration if a court finds the claims obvious or if a generic label avoids the patented use.

Key Takeaways

• Cubist sued Hospira over an ANDA for generic daptomycin, the active ingredient in Cubicin.
• The case was filed in the District of Delaware as 1:12-cv-01142.
• The asserted claims primarily concerned daptomycin dosing and treatment methods.
• The district court initially ruled in Cubist’s favor on material infringement and validity issues.
• The Federal Circuit reversed key obviousness findings in 805 F.3d 1112.
• The decision weakened Cubist’s dosing-patent barrier to Hospira’s generic entry.
• The dispute involved Hatch-Waxman Paragraph IV litigation, not biosimilar litigation.
• Cubicin’s remaining protection depended on formulation, process, method-of-use and later-issued patents.
• The case increased generic-entry risk for a product that generated more than $1 billion in annual sales.
• The Federal Circuit decision was a merits ruling; no public settlement was the principal reported disposition.

FAQs About Cubist v. Hospira and Cubicin Patent Litigation

What was Cubist’s main allegation against Hospira?

Cubist alleged that Hospira’s proposed generic daptomycin product and labeling would infringe Cubicin patents covering daptomycin dosing and treatment.

Was Hospira’s daptomycin product a biosimilar?

No. Daptomycin is a small-molecule drug, and Hospira pursued FDA approval through the ANDA pathway.

What is the most important case citation?

The principal Federal Circuit authority is Cubist Pharmaceuticals, Inc. v. Hospira, Inc., 805 F.3d 1112 (Fed. Cir. 2015).

Did the Federal Circuit invalidate every Cubicin patent?

No. The decision addressed the asserted claims and patents before the court. It did not automatically invalidate every Cubicin-related patent.

Why did the case matter to Merck?

Merck acquired Cubist while Cubicin remained a major revenue product. The Federal Circuit’s ruling increased the risk that generic daptomycin competition could reach the market before the nominal expiration of all Cubicin-related patents.

References

1. Cubist Pharmaceuticals, Inc. v. Hospira, Inc., 75 F. Supp. 3d 641 (D. Del. 2014).

2. Cubist Pharmaceuticals, Inc. v. Hospira, Inc., 805 F.3d 1112 (Fed. Cir. 2015).

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book.

4. Cubist Pharmaceuticals, Inc. (2014). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

5. Merck & Co., Inc. (2015). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.